Life Science

An activator of sGC that binds to a regulatory site, resulting in activation in an NO-independent manner (Kd = 3.2 nM) reduces hypertension, limits cardiomyocyte hypertrophy, protects against ischemia/reperfusion injury, and reduces morbidity and

An activator of sGC that binds to a regulatory site, resulting in activation in an NO-independent manner (Kd = 3.2 nM) reduces hypertension, limits cardiomyocyte hypertrophy, protects against ischemia/reperfusion injury, and reduces morbidity and

An activator of sGC that binds to a regulatory site, resulting in activation in an NO-independent manner (Kd = 3.2 nM) reduces hypertension, limits cardiomyocyte hypertrophy, protects against ischemia/reperfusion injury, and reduces morbidity and

A partial receptor agonist of mGlu4, effective at 100 &microM, with no activity at other mGlu receptor subtypes induces apoptosis of T cells at 300-500 &microM.

A partial receptor agonist of mGlu4, effective at 100 &microM, with no activity at other mGlu receptor subtypes induces apoptosis of T cells at 300-500 &microM.

A tetracyclic lantibiotic that demonstrates antiviral activity against HSV-1 also used as a probe for analyzing the transbilayer movement of phosphatidylethanolamine.

A tetracyclic lantibiotic that demonstrates antiviral activity against HSV-1 also used as a probe for analyzing the transbilayer movement of phosphatidylethanolamine.

A selective PPAR&alpha agonist (EC₅₀ = 20 &microM) that has been shown to lower adipose tissue weight and reduce plasma insulin concentrations in obese rats and has been used clinically in the treatment of dyslipidemia.

A selective PPAR&alpha agonist (EC₅₀ = 20 &microM) that has been shown to lower adipose tissue weight and reduce plasma insulin concentrations in obese rats and has been used clinically in the treatment of dyslipidemia.

A selective PPAR&alpha agonist (EC₅₀ = 20 &microM) that has been shown to lower adipose tissue weight and reduce plasma insulin concentrations in obese rats and has been used clinically in the treatment of dyslipidemia.

A fluoroquinolone antibiotic widely used as an antimicrobial and immunomodulatory agent functions by inhibiting DNA A fluoroquinolone antibiotic widely used as an antimicrobial and immunomodulatory agent functions by inhibiting DNA gyrase (a type

A fluoroquinolone antibiotic widely used as an antimicrobial and immunomodulatory agent functions by inhibiting DNA A fluoroquinolone antibiotic widely used as an antimicrobial and immunomodulatory agent functions by inhibiting DNA gyrase (a type